Overview

Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of bacterial conjunctivitis
Phase:
Phase 2
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Besifloxacin